Migraine is a neurological disorder, involving nerve pathways and brain chemicals. It is an uncertainty in the way the brain deals with incoming sensory information, and that uncertainty can be influenced by physiological changes like sleep, exercise and hunger.
It is one of the most common and most prevalent neurological disease with extremely incapacitating neurological symptoms. It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face. It is an exceptionally debilitating collection of neurological symptoms that usually includes a severe throbbing recurring pain on one side of the head. However, in one-third of migraine attacks, both sides are affected.
Migraine is classified by the nature of the attack and its frequency as Acute, Chronic, and Episodic Migraine. Before puberty, migraine is more common in boys than in girls. As adolescence approaches, the incidence and prevalence of migraine increase more rapidly in girls than in boys, mainly driven due to hormonal changes.
The Migraine market report covers emerging drugs, current treatment practices, Migraine market share of the individual therapies, current and forecasted Migraine Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Migraine treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Migraine Market Key Facts
The World Health Organization’s disability rating for migraine, ranks it as the 19th most common reason for disability.
According to the Migraine Trust Organization, it is ranked globally as the 7th most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.
According to the Migraine Research Foundation, it is an extraordinary prevalent neurological disease. About 39 million people in the US and 1 billion people all over the globe are affected by migraine.
Visit For Sample Pages:
Key Benefits of Migraine Market Report
Migraine market report provides an in-depth analysis of Migraine Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Migraine market report will help in developing business strategies by understanding the Migraine Market trends & developments, key players and future market competition that will shape and drive the Migraine market in the upcoming years.
The Migraine market report covers Migraine current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Migraine market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Migraine market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The Migraine epidemiology section covers insights about historical and current Migraine patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Migraine Drugs Uptake and Key Market Players
The Migraine Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched in the market during the study period. The analysis covers Migraine market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
There is a vast unmet need in the current migraine treatment options that can be summarized into efficacy, tolerability issues, and lack of migraine-specific treatments besides the triptans. This has facilitated the development of treatments with the patients facing high unmet medical needs. Expected launch of emerging therapies, such as INP104 (Impel NeuroPharma), AXS-07 (Axsome Therapeutics), M207/ADAM Zolmitriptan (Zosano Pharma Corporation), Rimegepant (Biohaven Pharmaceuticals), etc. are expected to create a noticeable increase in the market size of Migraine in the upcoming years.
Key players, such as Axsome Therapeutics, IMPAX Laboratories, Impel NeuroPharma, Zosano Pharma Corporation, Biohaven Pharmaceuticals, and many others are involved in developing therapies for Migraine.
Table of Contents
1. Key Insights
2. Executive Summary
3. Migraine Competitive Intelligence Analysis
4. Migraine Market Overview at a Glance
5. Migraine Disease Background and Overview
6. Migraine Patient Journey
7. Migraine Epidemiology and Patient Population
8. Migraine Treatment Algorithm, Current Treatment, and Medical Practices
9. Migraine Unmet Needs
10. Key Endpoints of Migraine Treatment
11. Migraine Marketed Products
12. Migraine Emerging Therapies
13. Migraine Seven Major Market Analysis
14. Attribute Analysis
15. Migraine Market Outlook (7 major markets)
16. Migraine Access and Reimbursement Overview
17. KOL Views on the Migraine Market.
18. Migraine Market Drivers
19. Migraine Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Migraine Epidemiology Forecast to 2030
DelveInsight’s Migraine Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Migraine in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Migraine Pipeline Insights, 2020
Migraine Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Migraine market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States